Eduardo Tschen
YOU?
Author Swipe
View article: Once-Daily Oral Sarecycline 1.5 mg/kg/day is Effective for Moderate to Severe Acne Vulgaris: Results from Two 12-Week, Phase 3, Randomized, Double-Blind Clinical Trials
Once-Daily Oral Sarecycline 1.5 mg/kg/day is Effective for Moderate to Severe Acne Vulgaris: Results from Two 12-Week, Phase 3, Randomized, Double-Blind Clinical Trials Open
not available.
View article: Safety of Hydrogen Peroxide Topical Solution, 40% (w/w) in Patients With Skin of Color and Seborrheic Keratoses: Pooled Analysis of Two Phase 3, Randomized, Double- Blind, Vehicle-Controlled, Parallel-Group Studies
Safety of Hydrogen Peroxide Topical Solution, 40% (w/w) in Patients With Skin of Color and Seborrheic Keratoses: Pooled Analysis of Two Phase 3, Randomized, Double- Blind, Vehicle-Controlled, Parallel-Group Studies Open
not available. Disclosures: Study sponsored by Aclaris.
View article: Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis
Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis Open
Crisaborole ointment had a low frequency of treatment-related AEs over 48 weeks of treatment of patients with AD.
View article: Crisaborole Topical Ointment, 2% in Patients Ages 2 to 17 Years with Atopic Dermatitis: A Phase 1b, Open‐Label, Maximal‐Use Systemic Exposure Study
Crisaborole Topical Ointment, 2% in Patients Ages 2 to 17 Years with Atopic Dermatitis: A Phase 1b, Open‐Label, Maximal‐Use Systemic Exposure Study Open
Background Phosphodiesterase‐4 (PDE4) is a promising target in atopic dermatitis (AD) treatment. The pharmacokinetics (PK), safety, and efficacy of crisaborole topical ointment, 2% (formerly AN2728) (Anacor Pharmaceuticals, Palo Alto, CA),…